Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
- G. SpitaleriAffiliated withIstituto Europeo di Oncologia
- , R. BerardiAffiliated withClinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I
- , C. PierantoniAffiliated withClinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I
- , T. De PasAffiliated withIstituto Europeo di Oncologia
- , C. NoberascoAffiliated withIstituto Europeo di Oncologia
- , C. LibbraAffiliated withPhilogen S.p.A.
- , R. González-IglesiasAffiliated withPhilogen S.p.A.
- , L. GiovannoniAffiliated withPhilogen S.p.A.
- , A. TasciottiAffiliated withPhilogen S.p.A.
- and 3 more
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
L19-TNF is an armed antibody that selectively targets human TNF to extra domain B-fibronectin on tumour blood vessels. We performed a phase I/II first-in-man trial with L19-TNF monotherapy in metastatic solid cancer patients to study safety and signs of clinical activity.
Six cohorts of patients were treated with increasing (1.3–13 μg/kg) doses of intravenous L19-TNF on day 1, 3, and 5 of repeated 3-weekly cycles, and 12 colorectal cancer patients were treated at 13 μg/kg. PK, antibody formation, changes in lymphocyte subsets, 5-HIAA plasma levels as well as safety and clinical activity were analysed.
Thirty-four patients received at least one L19-TNF dose. The serum half-life of L19-TNF at 13 μg/kg was 33.6 min, and maximum peak serum concentration was 73.14 μg/L. Mild chills, nausea and vomiting but no haemato- or unexpected toxicity were observed. Grade 3 lumbar pain in bone metastasis was the only dose-limiting toxicity found in one patient. Objective tumour responses were not detected. Transient stable disease occurred in 19 of 31 evaluable patients.
Intravenous L19-TNF on day 1, 3, and 5 of a 3-weekly schedule was safe up to 13 μg/kg, but did not result in objective tumour responses. The maximally tolerated dose (MTD) was not reached, allowing for further dose escalation of L19-TNF possibly in combination with chemotherapy.
KeywordsArmed antibody Immunocytokine L19-TNF Phase I/II trial Vascular targeting Vasodisruptive therapy
- Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
Journal of Cancer Research and Clinical Oncology
Volume 139, Issue 3 , pp 447-455
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Armed antibody
- Phase I/II trial
- Vascular targeting
- Vasodisruptive therapy
- Industry Sectors
- Author Affiliations
- 1. Istituto Europeo di Oncologia, Milan, Italy
- 2. Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Ancona, Italy
- 3. Philogen S.p.A., La Lizza 7, 53100, Siena, Italy
- 4. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Str. 10, 8093, Zurich, Switzerland
- 5. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy